Combining radiotherapy and chemotherapy doubles two-year survival in glioblastoma

Combining radiotherapy and chemotherapy doubles two-year survival in glioblastoma
Image: Intellect (generated)

In short: A review of clinical management for glioblastoma and other malignant gliomas, the most common primary brain cancers, found that current standard treatment—radiotherapy combined with the chemotherapy drug temozolomide—roughly doubles two-year survival to 27% compared with earlier approaches, though long-term outcomes for patients remain poor.

The review found that few risk factors for these tumors are firmly established: it names exposure to ionizing radiation and a small number of inherited genetic syndromes as the clearest links, while other suspected triggers, including cell phone use, remain unconfirmed. Newer options such as the drug bevacizumab are being explored, and grade III tumors are comparatively understudied.

This is a literature review of research published between 2000 and 2013 rather than a new clinical trial, so it summarizes existing studies rather than testing a treatment directly; it also predates more recent advances in glioma treatment.

Why it matters: Standard chemo-radiotherapy improves short-term survival in glioblastoma, but this aggressive brain cancer remains very hard to treat.

Opens the Intellect+ feed with this card first. Swipe up for the next one.

Sources

To cite this card, link to https://intellectplus.co.uk/app/science-research-current-treatments-for-glioblastoma-improve-survival-but-lea.

How we source, check and correct cards: Editorial standards.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

Finding something worth knowing…